Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need

The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19 deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR-tyrosine kinase inhibitors (TKIs). Less is known about uncommon mutations (10–15% of EGFR mutations). The predominant mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pretelli, Giulia, Spagnolo, Calogera Claudia, Ciappina, Giuliana, Santarpia, Mariacarmela, Pasello, Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218597/
https://www.ncbi.nlm.nih.gov/pubmed/37240224
http://dx.doi.org/10.3390/ijms24108878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218597/
https://www.ncbi.nlm.nih.gov/pubmed/37240224
http://dx.doi.org/10.3390/ijms24108878

Ejemplares similares